Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Polymer reduces drug conjugate immunogenicity

Substitute for polyethylene glycol enhances performance of existing immune-hindered drugs

by Stu Borman
December 5, 2016 | A version of this story appeared in Volume 94, Issue 48

An analog of polyethylene glycol (PEG) causes fewer immune reactions than PEG. PEG conjugation has been widely used to increase the longevity of drug action and protect drug molecules from being attacked by the immune system. However, prior exposure to PEG from its widespread use in consumer products, foods, and drugs has caused many people to develop immune reactions to the polymer itself, potentially reducing the efficacy of PEG­ylated drugs and causing unwanted side effects. To address this problem, Ashutosh Chilkoti of Duke University and coworkers developed a brush polymer called POEGMA, poly[oligo(ethylene glycol) methyl ether methacrylate], as a PEG substitute (Nat. Biomed. Eng. 2016, DOI: 10.1038/s41551-016-0002). They used a technique called in situ atom transfer radical polymerization to conjugate POEGMAs having different numbers of ethylene glycol side chains to exendin-4, a therapeutic peptide used clinically to treat type 2 diabetes. The conjugates reduced or eliminated immune interactions with preexisting PEG antibodies in patient plasma samples compared with those of two FDA-approved PEG­ylated protein drugs. And the conjugates didn’t reduce drug efficacy, as tested in mice. The findings suggest that POEGMA may be an attractive next-generation replacement for PEG­ylation of peptide and protein drugs.

Cartoon of extendin-POEGMA conjugate
Credit: Nat. Biomed. Eng.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.